What is Poppins?
Founded in 2018 and formerly known as Mila, Poppins is a French private healthcare technology firm headquartered in Palaiseau. The company specializes in developing a clinically validated therapeutic application designed to aid children aged 7 to 11 who experience dyslexia and related learning disorders. By integrating music-based interactive exercises, developed in collaboration with speech therapists and neurologists, Poppins aims to enhance crucial cognitive functions such as reading, memory, and motor skills. The platform serves as a bridge between healthcare and educational tools, supporting the cognitive development of children. Its recognition by the Fédération Française des DYS highlights its impact and credibility within the sector.
How much funding has Poppins raised?
Poppins has raised a total of $14.5M across 2 funding rounds:
Other Financing Round
$8.8M
Other Financing Round
$5.7M
Other Financing Round (2023): $8.8M with participation from Allianz France, HEC Alumni, and Eurazeo
Other Financing Round (2025): $5.7M led by Kurma Partners, BNP Paribas Développement, Eurazeo, Verve Ventures, Bpifrance, and Racine
Key Investors in Poppins
Kurma Partners
Kurma Partners is a key European player in financing innovation in healthcare and biotechnology, from pre-seed to growth capital, with a strong focus on innovative drug development approaches and venture capital financings of innovative young companies in Biotech and MedTech.
BNP Paribas Développement
BNP Paribas Développement, a subsidiary of BNP Paribas, invests its own funds to support the long-term development of SMEs and mid-sized companies, and high-potential startups offering innovative technologies or applications.
Eurazeo
Eurazeo is a leading global investment company supporting companies of all sizes in their development through private equity, venture capital, real estate, and private debt, offering deep sector expertise and a gateway to global markets.
What's next for Poppins?
The substantial enterprise-level funding and recent strategic investment signal Poppins' readiness for accelerated scaling and market expansion. With a focus on digital health and educational software for children with learning disorders, the company is well-positioned to further develop its therapeutic application and reach a broader audience. Future strategic initiatives will likely involve enhancing the platform's clinical validation, expanding its reach into new educational markets, and potentially exploring partnerships with healthcare providers and educational institutions. The consistent backing from prominent investors suggests a clear path towards solidifying its position as a leader in assistive learning technologies.
See full Poppins company page
